T Cell Immunobiology and Cytokine Storm of COVID-19

Overview

Journal Scand J Immunol

Specialty Allergy & Immunology

Date 2020 Oct 28

PMID 33113222

Citations 65

Authors

Xiao-Hua Luo

Yan Zhu

Jian Mao

Rui-Chan Du

Affiliations

Soon will be listed here.

Abstract

2019 coronavirus disease (COVID-19) presents as a newly recognized pneumonia and could rapidly progress into acute respiratory distress syndrome which has brought about a global pandemic. Until now, no curative therapy has been strongly recommended for COVID-19 except for personalized supportive care. T cells and virus-specific T cells are essential to protect against virus infection, including COVID-19. Delayed immune reconstitution (IR) and cytokine storm (CS) remain serious obstacles for the cure of COVID-19. Most COVID-19 patients, especially among elderly patients, had marked lymphopenia and increased neutrophils, but T cell counts in severe COVID-19 patients surviving the disease gradually restored later. Elevated pro-inflammatory cytokines, particularly IL-6, IL-10, IL-2 and IL-17, and exhausted T cells are found in peripheral blood and the lungs. It suggests that Thymosin α1 and adoptive COVID-19-specific T cells could improve IR, while convalescent plasma, IL-6 blockade, mesenchymal stem cells and corticosteroids could suppress CS. More clinical studies in this field worldwide are urgently warranted to pave the way for therapy of COVID-19 in the future.

Citing Articles

Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error.

Salemi N, Shojaie B, Bolourinejad P, Sherkat R, Zamanifar A, Ghaedrahmati F Adv Biomed Res. 2024; 13:112.

PMID: 39717240 PMC: 11665184. DOI: 10.4103/abr.abr_134_23.

The impact of SARS-CoV-2 infection on immunity reconstitution among pediatric patients after allogeneic hematopoietic stem cell transplantation: a propensity score-matched analysis.

Wang X, Liu L, Zhang L, Shang Y, Chen X, Ren Y Front Pediatr. 2024; 12:1489648.

PMID: 39639950 PMC: 11617172. DOI: 10.3389/fped.2024.1489648.

Identification of potential biomarkers and drug of ischemic stroke in patients with COVID-19 through machine learning.

Wang S, Tai Y, Yang X, Li P, Wang H, Tan Y Heliyon. 2024; 10(20):e39039.

PMID: 39502238 PMC: 11536010. DOI: 10.1016/j.heliyon.2024.e39039.

Radiological changes in the thymus in patients who have had COVID-19 and in vaccinated persons who have not had COVID-19: a CT study.

Demir B, Sogutlugil M, Cankal F Radiologie (Heidelb). 2024; 64(Suppl 1):139-144.

PMID: 39259290 DOI: 10.1007/s00117-024-01363-4.

A Multi-Machine Learning Consensus Model Based on Clinical Features Reveals That Interleukin-10 Derived from Monocytes Leads to a Poor Prognosis in Patients with Coronavirus Disease-2019.

Yu J, Zhang Y, Ye Z, Tang K, Ma Y, Fu L J Inflamm Res. 2024; 17:5923-5942.

PMID: 39247837 PMC: 11378990. DOI: 10.2147/JIR.S472099.

References

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

Zhu F, Guan X, Li Y, Huang J, Jiang T, Hou L . Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396(10249):479-488. PMC: 7836858. DOI: 10.1016/S0140-6736(20)31605-6. View

Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez S, Dan J . Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020; 370(6512):89-94. PMC: 7574914. DOI: 10.1126/science.abd3871. View

Cameron M, Ran L, Xu L, Danesh A, Bermejo-Martin J, Cameron C . Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007; 81(16):8692-706. PMC: 1951379. DOI: 10.1128/JVI.00527-07. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S . Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003; 24 Suppl 4:S217-21. DOI: 10.1007/s10072-003-0081-7. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

10.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

11.

Perruccio K, Bonifazi P, Topini F, Tosti A, Bozza S, Aloisi T . Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci. 2010; 1194:153-61. DOI: 10.1111/j.1749-6632.2010.05486.x. View

12.

Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L . Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis. 2020; 221(11):1762-1769. PMC: 7184346. DOI: 10.1093/infdis/jiaa150. View

13.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

14.

Huang K, Su I, Theron M, Wu Y, Lai S, Liu C . An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2004; 75(2):185-94. PMC: 7166886. DOI: 10.1002/jmv.20255. View

15.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

16.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

17.

Alattar R, Ibrahim T, Shaar S, Abdalla S, Shukri K, Daghfal J . Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020; 92(10):2042-2049. PMC: 7267594. DOI: 10.1002/jmv.25964. View

18.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

19.

Yao X, Li T, He Z, Ping Y, Liu H, Yu S . [A pathological report of three COVID-19 cases by minimal invasive autopsies]. Zhonghua Bing Li Xue Za Zhi. 2020; 49(5):411-417. DOI: 10.3760/cma.j.cn112151-20200312-00193. View

20.

Thevarajan I, Nguyen T, Koutsakos M, Druce J, Caly L, van de Sandt C . Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020; 26(4):453-455. PMC: 7095036. DOI: 10.1038/s41591-020-0819-2. View